SRX Global and CERO 1236 SPV enter agreement to acquire CERo Therapeutics
SRX Global and CERO 1236, a wholly-owned SPV, entered into a definitive agreement to acquire CERo Therapeutics, an innovative cellular immunotherapy company developing CER 1236 for hematologic malignancies.